-
公开(公告)号:US20230339960A1
公开(公告)日:2023-10-26
申请号:US18342977
申请日:2023-06-28
申请人: Pfizer Inc.
发明人: JOHN DAVID TRZUPEK , KATHERINE LIN LEE , MARK EDWARD BUNNAGE , SEUNGIL HAN , DAVID HEPWORTH , FRANK ELDRIDGE LOVERING , JOHN PAUL MATHIAS , NIKOLAOS PAPAIOANNOU , BETSY SUSAN PIERCE , JOSEPH WALTER STROHBACH , STEPHEN WAYNE WRIGHT , CHRISTOPH WOLFGANG ZAPF , LORI KRIM GAVRIN , ARTHUR LEE , DAVID RANDOLPH ANDERSON , KEVIN JOSEPH CURRAN , CHRISTOPH MARTIN DEHNHARDT , EDDINE SAIAH , JOEL ADAM GOLDBERG , XIAOLUN WANG , HORNG-CHIH HUANG , RICHARD VARGAS , MICHAEL DENNIS LOWE , AKSHAY PATNY
IPC分类号: C07D491/056 , C07F7/18 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , A61K31/40
CPC分类号: C07D491/056 , C07F7/1804 , A61K31/4015 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/517 , A61K31/5377 , A61K31/541 , A61K45/06 , C07C69/94 , C07D207/08 , C07D207/26 , C07D207/267 , C07D207/273 , C07D209/52 , C07D215/48 , C07D217/02 , C07D217/22 , C07D217/24 , C07D239/86 , C07D239/88 , C07D263/24 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D498/04 , A61K31/40
摘要: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia,
as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.